Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Breast Neoplasms | 314 | 2024 | 21065 | 7.230 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 81 | 2023 | 938 | 6.950 |
Why?
|
Breast | 81 | 2024 | 1980 | 5.800 |
Why?
|
Carcinoma, Ductal, Breast | 61 | 2023 | 1094 | 4.990 |
Why?
|
Carcinoma in Situ | 54 | 2023 | 796 | 4.180 |
Why?
|
Mastectomy, Segmental | 44 | 2020 | 965 | 4.090 |
Why?
|
Carcinoma, Lobular | 27 | 2024 | 490 | 3.440 |
Why?
|
Carcinoma | 23 | 2023 | 2334 | 2.840 |
Why?
|
Breast Diseases | 32 | 2021 | 443 | 2.660 |
Why?
|
Phyllodes Tumor | 4 | 2021 | 53 | 1.820 |
Why?
|
Neoplasm Recurrence, Local | 79 | 2024 | 9274 | 1.770 |
Why?
|
Carcinoma, Papillary | 7 | 2021 | 785 | 1.620 |
Why?
|
Cadherins | 10 | 2024 | 898 | 1.420 |
Why?
|
Immunohistochemistry | 48 | 2024 | 11064 | 1.400 |
Why?
|
Receptors, Estrogen | 40 | 2024 | 2202 | 1.370 |
Why?
|
Fibrocystic Breast Disease | 12 | 2017 | 103 | 1.340 |
Why?
|
Frozen Sections | 4 | 2013 | 153 | 1.250 |
Why?
|
Receptor, erbB-2 | 29 | 2024 | 2544 | 1.200 |
Why?
|
Radiation Oncology | 7 | 2016 | 563 | 1.030 |
Why?
|
Neoadjuvant Therapy | 8 | 2024 | 2811 | 1.020 |
Why?
|
Precancerous Conditions | 15 | 2016 | 978 | 0.970 |
Why?
|
Carcinoma, Acinar Cell | 2 | 2023 | 62 | 0.970 |
Why?
|
Pathology, Clinical | 9 | 2024 | 375 | 0.910 |
Why?
|
Hyperplasia | 30 | 2023 | 1158 | 0.900 |
Why?
|
Neoplasm, Residual | 8 | 2022 | 1008 | 0.880 |
Why?
|
Biopsy, Needle | 12 | 2008 | 1633 | 0.870 |
Why?
|
Neoplasm Invasiveness | 35 | 2023 | 3618 | 0.860 |
Why?
|
Female | 326 | 2024 | 391011 | 0.850 |
Why?
|
Receptors, Steroid | 1 | 2023 | 154 | 0.810 |
Why?
|
Mucocele | 1 | 2022 | 51 | 0.800 |
Why?
|
Epithelial Cells | 16 | 2014 | 3665 | 0.770 |
Why?
|
Adenocarcinoma, Mucinous | 6 | 2022 | 517 | 0.690 |
Why?
|
Fibroma | 1 | 2021 | 190 | 0.680 |
Why?
|
Biopsy | 42 | 2020 | 6775 | 0.670 |
Why?
|
Humans | 368 | 2024 | 760261 | 0.660 |
Why?
|
Salivary Gland Neoplasms | 1 | 2023 | 304 | 0.650 |
Why?
|
Receptors, Nerve Growth Factor | 1 | 2019 | 198 | 0.630 |
Why?
|
Breast Neoplasms, Male | 1 | 2019 | 221 | 0.590 |
Why?
|
In Situ Hybridization, Fluorescence | 8 | 2023 | 2500 | 0.590 |
Why?
|
Gene Fusion | 1 | 2019 | 354 | 0.560 |
Why?
|
Mammography | 25 | 2024 | 2452 | 0.550 |
Why?
|
Mammary Glands, Human | 6 | 2021 | 204 | 0.540 |
Why?
|
Sex Reassignment Surgery | 2 | 2020 | 157 | 0.540 |
Why?
|
Receptors, Progesterone | 24 | 2018 | 1122 | 0.540 |
Why?
|
Lymph Nodes | 11 | 2021 | 3491 | 0.520 |
Why?
|
Genes, BRCA1 | 6 | 2014 | 769 | 0.500 |
Why?
|
Surgery, Computer-Assisted | 2 | 2019 | 1007 | 0.500 |
Why?
|
Hemangiosarcoma | 1 | 2017 | 218 | 0.480 |
Why?
|
Isocitrate Dehydrogenase | 2 | 2020 | 927 | 0.470 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 5 | 2024 | 1090 | 0.440 |
Why?
|
Gene Expression Profiling | 14 | 2024 | 9388 | 0.420 |
Why?
|
Prognosis | 59 | 2024 | 29636 | 0.410 |
Why?
|
Mastectomy | 21 | 2019 | 1834 | 0.400 |
Why?
|
Receptors, Androgen | 5 | 2024 | 1075 | 0.400 |
Why?
|
Pathology | 3 | 2022 | 270 | 0.390 |
Why?
|
Middle Aged | 147 | 2024 | 220175 | 0.390 |
Why?
|
Radiography, Interventional | 2 | 2019 | 1112 | 0.390 |
Why?
|
Lymphatic Metastasis | 23 | 2019 | 2945 | 0.380 |
Why?
|
Neoplasm Staging | 37 | 2024 | 11141 | 0.370 |
Why?
|
Practice Guidelines as Topic | 4 | 2017 | 7468 | 0.370 |
Why?
|
Neoplasms, Multiple Primary | 7 | 2015 | 586 | 0.360 |
Why?
|
Diagnosis, Differential | 20 | 2021 | 12968 | 0.350 |
Why?
|
Observer Variation | 11 | 2024 | 2596 | 0.340 |
Why?
|
Adult | 134 | 2024 | 219847 | 0.340 |
Why?
|
Fibroadenoma | 2 | 2016 | 41 | 0.340 |
Why?
|
Genetic Association Studies | 2 | 2020 | 2716 | 0.330 |
Why?
|
Combined Modality Therapy | 38 | 2019 | 8551 | 0.320 |
Why?
|
Stromal Cells | 9 | 2021 | 1327 | 0.320 |
Why?
|
Radiotherapy, Adjuvant | 12 | 2017 | 1790 | 0.320 |
Why?
|
Genes, erbB-2 | 6 | 2007 | 163 | 0.320 |
Why?
|
Receptor, IGF Type 1 | 1 | 2011 | 380 | 0.310 |
Why?
|
Axilla | 12 | 2019 | 618 | 0.310 |
Why?
|
Pathology, Surgical | 2 | 2014 | 151 | 0.300 |
Why?
|
Reference Standards | 2 | 2021 | 1004 | 0.300 |
Why?
|
Nipples | 3 | 2023 | 221 | 0.290 |
Why?
|
Risk Factors | 53 | 2021 | 74269 | 0.290 |
Why?
|
Tumor Suppressor Protein p53 | 8 | 2016 | 2927 | 0.290 |
Why?
|
Patient Selection | 2 | 2019 | 4276 | 0.290 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2016 | 2866 | 0.280 |
Why?
|
Chemotherapy, Adjuvant | 16 | 2024 | 3531 | 0.280 |
Why?
|
Breast Cyst | 1 | 2006 | 8 | 0.280 |
Why?
|
Immunoenzyme Techniques | 12 | 2013 | 1705 | 0.270 |
Why?
|
Neovascularization, Pathologic | 7 | 2022 | 2641 | 0.260 |
Why?
|
Medical Oncology | 6 | 2023 | 2321 | 0.260 |
Why?
|
Epithelium | 7 | 2017 | 1605 | 0.260 |
Why?
|
Aged | 88 | 2024 | 168995 | 0.250 |
Why?
|
Heterozygote | 3 | 2012 | 2797 | 0.240 |
Why?
|
Immunophenotyping | 6 | 2023 | 1870 | 0.240 |
Why?
|
Aged, 80 and over | 41 | 2022 | 58947 | 0.240 |
Why?
|
Sentinel Lymph Node Biopsy | 2 | 2019 | 727 | 0.240 |
Why?
|
Ki-67 Antigen | 4 | 2023 | 631 | 0.240 |
Why?
|
Tissue Array Analysis | 9 | 2012 | 551 | 0.240 |
Why?
|
Consensus | 6 | 2023 | 3106 | 0.240 |
Why?
|
Retinoblastoma Binding Proteins | 1 | 2024 | 102 | 0.230 |
Why?
|
Genetic Predisposition to Disease | 5 | 2017 | 17766 | 0.230 |
Why?
|
Cell Nucleus | 8 | 2011 | 2909 | 0.220 |
Why?
|
Catenins | 2 | 2021 | 41 | 0.220 |
Why?
|
Testosterone | 3 | 2024 | 2469 | 0.220 |
Why?
|
Papilloma, Intraductal | 2 | 2020 | 21 | 0.220 |
Why?
|
Keratins | 7 | 2011 | 497 | 0.220 |
Why?
|
Biological Products | 2 | 2022 | 914 | 0.210 |
Why?
|
Antineoplastic Agents, Hormonal | 6 | 2019 | 1523 | 0.210 |
Why?
|
Case-Control Studies | 22 | 2021 | 22041 | 0.210 |
Why?
|
World Health Organization | 3 | 2024 | 1319 | 0.200 |
Why?
|
Receptors, Thyroid Hormone | 1 | 2023 | 199 | 0.200 |
Why?
|
Gene Expression | 6 | 2017 | 7592 | 0.200 |
Why?
|
Specimen Handling | 4 | 2018 | 708 | 0.200 |
Why?
|
Mucins | 2 | 2022 | 568 | 0.200 |
Why?
|
Salivary Glands | 1 | 2023 | 229 | 0.200 |
Why?
|
Parity | 4 | 2021 | 925 | 0.200 |
Why?
|
Societies, Medical | 6 | 2016 | 3903 | 0.200 |
Why?
|
Mutation | 13 | 2024 | 29950 | 0.190 |
Why?
|
Markov Chains | 2 | 2024 | 971 | 0.190 |
Why?
|
Cohort Studies | 25 | 2022 | 41317 | 0.190 |
Why?
|
Calcinosis | 7 | 2014 | 1478 | 0.190 |
Why?
|
Microscopy | 2 | 2017 | 881 | 0.180 |
Why?
|
Neoplasm Proteins | 8 | 2007 | 3613 | 0.180 |
Why?
|
Tamoxifen | 5 | 2019 | 963 | 0.180 |
Why?
|
Predictive Value of Tests | 14 | 2021 | 15273 | 0.180 |
Why?
|
Artificial Intelligence | 3 | 2024 | 2557 | 0.180 |
Why?
|
Odds Ratio | 12 | 2017 | 9712 | 0.180 |
Why?
|
Paris | 1 | 2019 | 50 | 0.170 |
Why?
|
Follow-Up Studies | 37 | 2020 | 39254 | 0.170 |
Why?
|
BRCA1 Protein | 5 | 2016 | 1146 | 0.170 |
Why?
|
United States | 27 | 2024 | 72363 | 0.170 |
Why?
|
Diagnostic Errors | 3 | 2017 | 1266 | 0.170 |
Why?
|
Neoplasms, Hormone-Dependent | 2 | 2014 | 412 | 0.170 |
Why?
|
Drug Therapy | 1 | 2003 | 504 | 0.170 |
Why?
|
Estrogen Replacement Therapy | 3 | 2013 | 1207 | 0.170 |
Why?
|
Microtomy | 2 | 1997 | 44 | 0.160 |
Why?
|
Urothelium | 1 | 2021 | 277 | 0.160 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 3 | 2022 | 896 | 0.160 |
Why?
|
Carcinoma, Ductal | 2 | 2010 | 98 | 0.160 |
Why?
|
Gene Expression Regulation, Neoplastic | 10 | 2024 | 8498 | 0.160 |
Why?
|
Image Interpretation, Computer-Assisted | 3 | 2017 | 3335 | 0.160 |
Why?
|
Image Processing, Computer-Assisted | 6 | 2020 | 8945 | 0.160 |
Why?
|
Risk | 16 | 2021 | 9629 | 0.160 |
Why?
|
Receptor, erbB-3 | 1 | 2020 | 143 | 0.160 |
Why?
|
Alcohol Drinking | 5 | 2013 | 4012 | 0.160 |
Why?
|
Proto-Oncogene Proteins c-ets | 1 | 2019 | 311 | 0.160 |
Why?
|
Physician-Patient Relations | 1 | 2012 | 3242 | 0.160 |
Why?
|
Antigens, CD | 5 | 2024 | 4002 | 0.150 |
Why?
|
Disease Progression | 14 | 2016 | 13505 | 0.150 |
Why?
|
Decision Making | 1 | 2012 | 3924 | 0.150 |
Why?
|
Endothelial Growth Factors | 4 | 2002 | 674 | 0.150 |
Why?
|
Reagent Kits, Diagnostic | 1 | 1999 | 238 | 0.150 |
Why?
|
Prospective Studies | 35 | 2020 | 54263 | 0.150 |
Why?
|
Plasma Cells | 1 | 2021 | 592 | 0.150 |
Why?
|
Necrosis | 4 | 2019 | 1612 | 0.150 |
Why?
|
Communication | 1 | 2012 | 3846 | 0.150 |
Why?
|
Gene Rearrangement | 1 | 2023 | 1122 | 0.150 |
Why?
|
Risk Assessment | 13 | 2024 | 24086 | 0.150 |
Why?
|
Cyclooxygenase 2 | 2 | 2011 | 600 | 0.150 |
Why?
|
Sarcoma | 2 | 2021 | 1786 | 0.150 |
Why?
|
Lymphokines | 4 | 2002 | 929 | 0.150 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 10 | 2022 | 11708 | 0.140 |
Why?
|
Cyclophosphamide | 4 | 2020 | 2220 | 0.140 |
Why?
|
Expert Testimony | 1 | 2020 | 361 | 0.140 |
Why?
|
Postmenopause | 6 | 2019 | 2503 | 0.140 |
Why?
|
Cicatrix | 2 | 2002 | 781 | 0.140 |
Why?
|
Muscle Cells | 2 | 2009 | 195 | 0.140 |
Why?
|
Patient Care Management | 1 | 2020 | 303 | 0.140 |
Why?
|
Reproducibility of Results | 9 | 2020 | 20048 | 0.140 |
Why?
|
Receptors, Growth Factor | 3 | 2002 | 326 | 0.130 |
Why?
|
Urogenital Neoplasms | 1 | 2017 | 135 | 0.130 |
Why?
|
Doxorubicin | 3 | 2020 | 2207 | 0.130 |
Why?
|
Nuclear Proteins | 1 | 2010 | 5793 | 0.130 |
Why?
|
Sensitivity and Specificity | 14 | 2006 | 14656 | 0.130 |
Why?
|
Retrospective Studies | 32 | 2022 | 80301 | 0.130 |
Why?
|
Menarche | 2 | 2021 | 529 | 0.130 |
Why?
|
Nurses | 8 | 2017 | 2468 | 0.130 |
Why?
|
Coloring Agents | 2 | 1997 | 561 | 0.130 |
Why?
|
Germ-Line Mutation | 2 | 2017 | 1843 | 0.120 |
Why?
|
Neoplasms, Second Primary | 4 | 2017 | 1060 | 0.120 |
Why?
|
Stereotaxic Techniques | 3 | 2014 | 549 | 0.120 |
Why?
|
Young Adult | 10 | 2022 | 58673 | 0.120 |
Why?
|
Watchful Waiting | 1 | 2019 | 510 | 0.120 |
Why?
|
Prostate | 1 | 2003 | 1793 | 0.120 |
Why?
|
Nanomedicine | 1 | 2017 | 290 | 0.120 |
Why?
|
Consensus Development Conferences, NIH as Topic | 1 | 2014 | 28 | 0.120 |
Why?
|
Myocardium | 5 | 1993 | 4688 | 0.120 |
Why?
|
Neoplasm Metastasis | 12 | 2014 | 4891 | 0.120 |
Why?
|
Incidence | 19 | 2020 | 21378 | 0.120 |
Why?
|
Radiotherapy | 6 | 2014 | 1505 | 0.110 |
Why?
|
Cisplatin | 1 | 2020 | 1642 | 0.110 |
Why?
|
Guidelines as Topic | 1 | 2020 | 1395 | 0.110 |
Why?
|
Carbon | 1 | 1997 | 669 | 0.110 |
Why?
|
Stem Cells | 3 | 2013 | 3525 | 0.110 |
Why?
|
Cytoplasm | 4 | 2011 | 1518 | 0.110 |
Why?
|
Nomograms | 1 | 2015 | 238 | 0.110 |
Why?
|
Treatment Outcome | 23 | 2014 | 64947 | 0.110 |
Why?
|
DNA Copy Number Variations | 2 | 2022 | 2008 | 0.110 |
Why?
|
Molecular Biology | 2 | 2010 | 581 | 0.110 |
Why?
|
Transcription Factors | 3 | 2011 | 12100 | 0.110 |
Why?
|
Coxsackievirus Infections | 1 | 1993 | 42 | 0.110 |
Why?
|
Survival Analysis | 10 | 2014 | 10185 | 0.110 |
Why?
|
Estrogen Receptor alpha | 2 | 2014 | 580 | 0.110 |
Why?
|
Androgens | 1 | 2020 | 1289 | 0.110 |
Why?
|
Receptor Protein-Tyrosine Kinases | 4 | 2002 | 1614 | 0.110 |
Why?
|
Adolescent | 18 | 2019 | 87747 | 0.100 |
Why?
|
Antineoplastic Protocols | 2 | 2002 | 50 | 0.100 |
Why?
|
High-Throughput Nucleotide Sequencing | 4 | 2021 | 3618 | 0.100 |
Why?
|
Blotting, Western | 3 | 2016 | 5039 | 0.100 |
Why?
|
Oncogene Proteins, Viral | 1 | 1994 | 341 | 0.100 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2013 | 319 | 0.100 |
Why?
|
American Cancer Society | 1 | 2012 | 62 | 0.100 |
Why?
|
Vascular Endothelial Growth Factor A | 6 | 2011 | 3483 | 0.100 |
Why?
|
Proto-Oncogene Proteins | 5 | 1999 | 4494 | 0.100 |
Why?
|
Genes, p53 | 4 | 2006 | 714 | 0.100 |
Why?
|
Mammaplasty | 2 | 2018 | 1239 | 0.100 |
Why?
|
Papilloma | 2 | 2008 | 141 | 0.100 |
Why?
|
Logistic Models | 8 | 2016 | 13311 | 0.100 |
Why?
|
Mesothelioma | 1 | 2017 | 806 | 0.090 |
Why?
|
Mitosis | 2 | 2011 | 1193 | 0.090 |
Why?
|
Lymph Node Excision | 8 | 2019 | 1305 | 0.090 |
Why?
|
DNA Mutational Analysis | 2 | 2016 | 4109 | 0.090 |
Why?
|
Polymerase Chain Reaction | 3 | 2016 | 6067 | 0.090 |
Why?
|
Molecular Typing | 1 | 2011 | 116 | 0.090 |
Why?
|
Technetium Tc 99m Sestamibi | 2 | 2002 | 173 | 0.090 |
Why?
|
Proportional Hazards Models | 12 | 2016 | 12532 | 0.090 |
Why?
|
Endocardium | 1 | 1992 | 246 | 0.090 |
Why?
|
Neoplasms, Basal Cell | 1 | 2010 | 31 | 0.090 |
Why?
|
Reproductive History | 3 | 2014 | 210 | 0.090 |
Why?
|
Ovarian Neoplasms | 4 | 2017 | 4875 | 0.090 |
Why?
|
Carcinoma, Neuroendocrine | 1 | 2015 | 346 | 0.090 |
Why?
|
Time Factors | 19 | 2018 | 40133 | 0.090 |
Why?
|
Fibrin | 1 | 1993 | 505 | 0.090 |
Why?
|
Molecular Imaging | 1 | 2017 | 817 | 0.090 |
Why?
|
Aneuploidy | 2 | 2011 | 551 | 0.090 |
Why?
|
Survival Rate | 10 | 2019 | 12806 | 0.090 |
Why?
|
Dietary Fiber | 3 | 2010 | 760 | 0.090 |
Why?
|
Gastrointestinal Neoplasms | 1 | 2017 | 951 | 0.090 |
Why?
|
Diet | 4 | 2014 | 8008 | 0.080 |
Why?
|
Disease-Free Survival | 8 | 2021 | 6830 | 0.080 |
Why?
|
Menopause | 5 | 2021 | 1640 | 0.080 |
Why?
|
Cardiomyopathy, Dilated | 2 | 1993 | 819 | 0.080 |
Why?
|
Chemokines, CXC | 2 | 2008 | 421 | 0.080 |
Why?
|
Calcium-Binding Proteins | 2 | 2005 | 1066 | 0.080 |
Why?
|
Staining and Labeling | 3 | 2005 | 1090 | 0.080 |
Why?
|
Histological Techniques | 3 | 2017 | 194 | 0.080 |
Why?
|
Adenocarcinoma | 7 | 2004 | 6310 | 0.080 |
Why?
|
Atherectomy, Coronary | 3 | 1993 | 146 | 0.080 |
Why?
|
Cell Lineage | 3 | 2013 | 2525 | 0.080 |
Why?
|
Randomized Controlled Trials as Topic | 5 | 2022 | 10340 | 0.080 |
Why?
|
Insulin-Like Growth Factor Binding Proteins | 1 | 2010 | 206 | 0.080 |
Why?
|
Repressor Proteins | 1 | 2019 | 2978 | 0.080 |
Why?
|
Apoptosis | 5 | 2010 | 9497 | 0.080 |
Why?
|
Urinary Bladder Neoplasms | 1 | 2021 | 2277 | 0.080 |
Why?
|
Registries | 3 | 2020 | 8449 | 0.080 |
Why?
|
Terminology as Topic | 2 | 2013 | 1534 | 0.080 |
Why?
|
DNA | 2 | 2022 | 7236 | 0.080 |
Why?
|
Endometriosis | 1 | 2016 | 871 | 0.080 |
Why?
|
Endometrial Neoplasms | 1 | 2017 | 1361 | 0.080 |
Why?
|
Genes, Neoplasm | 1 | 2010 | 370 | 0.080 |
Why?
|
Granuloma | 2 | 1987 | 328 | 0.070 |
Why?
|
Early Detection of Cancer | 2 | 2020 | 3215 | 0.070 |
Why?
|
Cell Transformation, Neoplastic | 3 | 2011 | 2823 | 0.070 |
Why?
|
Nuts | 1 | 2010 | 263 | 0.070 |
Why?
|
Myocarditis | 2 | 1993 | 766 | 0.070 |
Why?
|
Heat-Shock Proteins | 1 | 2011 | 795 | 0.070 |
Why?
|
Sublingual Gland | 1 | 1987 | 11 | 0.070 |
Why?
|
Cathepsins | 1 | 2008 | 242 | 0.070 |
Why?
|
Salivary Gland Diseases | 1 | 1987 | 37 | 0.070 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 4 | 1998 | 1408 | 0.070 |
Why?
|
Age Factors | 14 | 2020 | 18415 | 0.070 |
Why?
|
Congresses as Topic | 1 | 2012 | 804 | 0.070 |
Why?
|
Sialadenitis | 1 | 1987 | 45 | 0.070 |
Why?
|
Secondary Prevention | 1 | 2013 | 1548 | 0.070 |
Why?
|
Carcinoma, Large Cell | 1 | 2007 | 113 | 0.070 |
Why?
|
Paraffin | 2 | 1996 | 37 | 0.070 |
Why?
|
Unnecessary Procedures | 1 | 2010 | 413 | 0.070 |
Why?
|
Oligonucleotide Array Sequence Analysis | 4 | 2013 | 3774 | 0.070 |
Why?
|
Diagnosis-Related Groups | 1 | 1988 | 450 | 0.070 |
Why?
|
Skin Neoplasms | 4 | 2017 | 5797 | 0.070 |
Why?
|
Histocompatibility Antigens | 1 | 1987 | 467 | 0.070 |
Why?
|
PTEN Phosphohydrolase | 1 | 2012 | 1115 | 0.070 |
Why?
|
Codon, Nonsense | 1 | 2007 | 282 | 0.070 |
Why?
|
Phenotype | 9 | 2017 | 16543 | 0.070 |
Why?
|
Myocytes, Smooth Muscle | 1 | 2010 | 685 | 0.070 |
Why?
|
Intestine, Large | 1 | 2005 | 68 | 0.060 |
Why?
|
Cranial Nerve Neoplasms | 1 | 1987 | 134 | 0.060 |
Why?
|
Body Mass Index | 5 | 2024 | 12901 | 0.060 |
Why?
|
DNA-Binding Proteins | 1 | 2023 | 9590 | 0.060 |
Why?
|
DNA, Neoplasm | 3 | 2013 | 1745 | 0.060 |
Why?
|
Trigeminal Nerve | 1 | 1987 | 248 | 0.060 |
Why?
|
Folic Acid | 1 | 2012 | 1309 | 0.060 |
Why?
|
Coronary Disease | 4 | 1993 | 5993 | 0.060 |
Why?
|
Factor VIII | 2 | 1998 | 350 | 0.060 |
Why?
|
Neoplastic Syndromes, Hereditary | 1 | 2007 | 243 | 0.060 |
Why?
|
Craniopharyngioma | 1 | 1987 | 277 | 0.060 |
Why?
|
Ultrasonography, Mammary | 2 | 2004 | 247 | 0.060 |
Why?
|
Managed Care Programs | 1 | 2010 | 939 | 0.060 |
Why?
|
Melanoma | 2 | 2017 | 5695 | 0.060 |
Why?
|
Multivariate Analysis | 8 | 2014 | 12156 | 0.060 |
Why?
|
Dietary Fats | 3 | 2014 | 1992 | 0.060 |
Why?
|
Microwaves | 3 | 1991 | 184 | 0.060 |
Why?
|
Histones | 1 | 2014 | 2583 | 0.060 |
Why?
|
Cell Communication | 2 | 2009 | 1642 | 0.060 |
Why?
|
Tissue Fixation | 2 | 2018 | 241 | 0.060 |
Why?
|
Carcinoma, Squamous Cell | 2 | 2017 | 4024 | 0.060 |
Why?
|
Sex Reassignment Procedures | 1 | 2024 | 64 | 0.060 |
Why?
|
Microcirculation | 3 | 2002 | 1279 | 0.060 |
Why?
|
Vascular Endothelial Growth Factors | 4 | 2002 | 749 | 0.060 |
Why?
|
Antibodies | 2 | 2008 | 2424 | 0.050 |
Why?
|
Keratin-7 | 1 | 2023 | 55 | 0.050 |
Why?
|
Head and Neck Neoplasms | 1 | 2017 | 2880 | 0.050 |
Why?
|
Magnetic Resonance Imaging | 6 | 2021 | 36247 | 0.050 |
Why?
|
Family Health | 2 | 2006 | 1258 | 0.050 |
Why?
|
Cell Division | 7 | 2004 | 4462 | 0.050 |
Why?
|
Male | 25 | 2024 | 359413 | 0.050 |
Why?
|
Computational Biology | 1 | 2014 | 3504 | 0.050 |
Why?
|
Decision Trees | 1 | 2024 | 506 | 0.050 |
Why?
|
S100 Proteins | 4 | 2005 | 218 | 0.050 |
Why?
|
Radiotherapy Dosage | 6 | 2004 | 2897 | 0.050 |
Why?
|
Government Agencies | 1 | 2022 | 161 | 0.050 |
Why?
|
Women's Health | 5 | 2004 | 2057 | 0.050 |
Why?
|
Insulin-Like Growth Factor I | 1 | 2010 | 1920 | 0.050 |
Why?
|
Estrogen Receptor Modulators | 1 | 2001 | 58 | 0.050 |
Why?
|
Biology | 1 | 2024 | 289 | 0.050 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2006 | 625 | 0.050 |
Why?
|
Antigens | 2 | 1987 | 1447 | 0.050 |
Why?
|
Neoplasms | 4 | 2021 | 22066 | 0.050 |
Why?
|
Radiopharmaceuticals | 2 | 2002 | 2633 | 0.050 |
Why?
|
Tumor Burden | 3 | 2013 | 1897 | 0.050 |
Why?
|
Lymphatic Vessel Tumors | 1 | 2001 | 2 | 0.050 |
Why?
|
Colonic Diseases | 1 | 1983 | 200 | 0.050 |
Why?
|
Tumor Cells, Cultured | 6 | 2007 | 6131 | 0.050 |
Why?
|
DNA Repair | 1 | 2010 | 2039 | 0.050 |
Why?
|
Keratin-5 | 2 | 2011 | 45 | 0.050 |
Why?
|
Cell Proliferation | 3 | 2014 | 10434 | 0.050 |
Why?
|
Cell Membrane | 1 | 2011 | 3683 | 0.050 |
Why?
|
In Situ Hybridization | 4 | 2002 | 1900 | 0.050 |
Why?
|
Membrane Proteins | 3 | 2007 | 7854 | 0.050 |
Why?
|
Enterocolitis, Pseudomembranous | 1 | 1983 | 265 | 0.050 |
Why?
|
Genes, erbB | 1 | 2000 | 5 | 0.050 |
Why?
|
Retinoblastoma Protein | 1 | 2024 | 671 | 0.050 |
Why?
|
Hematoxylin | 2 | 1993 | 60 | 0.050 |
Why?
|
Eosine Yellowish-(YS) | 2 | 1993 | 69 | 0.050 |
Why?
|
Cardiology | 1 | 1992 | 1723 | 0.050 |
Why?
|
RNA, Messenger | 7 | 2013 | 12762 | 0.050 |
Why?
|
Attitude of Health Personnel | 1 | 2014 | 3870 | 0.040 |
Why?
|
Skin | 2 | 1993 | 4468 | 0.040 |
Why?
|
Meningeal Neoplasms | 2 | 1987 | 1248 | 0.040 |
Why?
|
Severity of Illness Index | 2 | 2010 | 15827 | 0.040 |
Why?
|
Autoanalysis | 1 | 2000 | 71 | 0.040 |
Why?
|
Genetic Variation | 2 | 2020 | 6540 | 0.040 |
Why?
|
Obesity | 1 | 2022 | 12915 | 0.040 |
Why?
|
Comparative Genomic Hybridization | 2 | 2013 | 473 | 0.040 |
Why?
|
Lymphatic Irradiation | 1 | 2000 | 115 | 0.040 |
Why?
|
Ploidies | 1 | 2000 | 275 | 0.040 |
Why?
|
Antineoplastic Agents | 5 | 2014 | 13629 | 0.040 |
Why?
|
Regression Analysis | 7 | 2010 | 6361 | 0.040 |
Why?
|
Core Binding Factor Alpha 2 Subunit | 1 | 2022 | 352 | 0.040 |
Why?
|
Cardiomyopathies | 1 | 1992 | 1945 | 0.040 |
Why?
|
Esthetics | 3 | 1998 | 326 | 0.040 |
Why?
|
Autophagy | 1 | 2007 | 1336 | 0.040 |
Why?
|
Lymphocytes | 1 | 1987 | 2612 | 0.040 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 3 | 2002 | 666 | 0.040 |
Why?
|
Intestine, Small | 1 | 2005 | 1207 | 0.040 |
Why?
|
Fluorescent Antibody Technique | 3 | 2013 | 2473 | 0.040 |
Why?
|
Aspirin | 1 | 2011 | 3365 | 0.040 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2017 | 5248 | 0.040 |
Why?
|
Calcium | 1 | 2012 | 5726 | 0.040 |
Why?
|
Statistics, Nonparametric | 2 | 2008 | 2852 | 0.040 |
Why?
|
Edema | 1 | 1983 | 772 | 0.040 |
Why?
|
Pituitary Neoplasms | 1 | 1987 | 1313 | 0.040 |
Why?
|
Elasticity | 1 | 2021 | 652 | 0.040 |
Why?
|
Hepatocyte Growth Factor | 2 | 1997 | 267 | 0.040 |
Why?
|
Hormone Replacement Therapy | 1 | 2004 | 756 | 0.040 |
Why?
|
Patient Compliance | 1 | 2009 | 2689 | 0.040 |
Why?
|
Saphenous Vein | 2 | 1992 | 538 | 0.040 |
Why?
|
Estrogen Antagonists | 1 | 2019 | 152 | 0.040 |
Why?
|
Health Care Costs | 2 | 2004 | 3257 | 0.040 |
Why?
|
Research Design | 3 | 2011 | 6181 | 0.040 |
Why?
|
Graft Occlusion, Vascular | 2 | 1992 | 560 | 0.040 |
Why?
|
Vitamin D | 1 | 2012 | 3293 | 0.040 |
Why?
|
Hormones | 1 | 2022 | 867 | 0.040 |
Why?
|
Paclitaxel | 1 | 2006 | 1738 | 0.040 |
Why?
|
Mass Screening | 2 | 2012 | 5422 | 0.040 |
Why?
|
Age Distribution | 2 | 2014 | 2893 | 0.040 |
Why?
|
Cost-Benefit Analysis | 3 | 2024 | 5507 | 0.040 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 3 | 2013 | 4573 | 0.040 |
Why?
|
Cyclin-Dependent Kinase 4 | 1 | 2021 | 556 | 0.040 |
Why?
|
Body Size | 1 | 2021 | 462 | 0.040 |
Why?
|
Aminopyridines | 1 | 2021 | 564 | 0.040 |
Why?
|
Cell Line, Tumor | 5 | 2014 | 16905 | 0.040 |
Why?
|
Meningioma | 1 | 1986 | 1220 | 0.040 |
Why?
|
SEER Program | 2 | 2013 | 1532 | 0.040 |
Why?
|
Mastectomy, Simple | 2 | 1993 | 23 | 0.040 |
Why?
|
Nephrosis, Lipoid | 1 | 2017 | 45 | 0.040 |
Why?
|
Animals | 14 | 2024 | 167940 | 0.040 |
Why?
|
Quality Control | 1 | 2000 | 827 | 0.040 |
Why?
|
Recurrence | 8 | 2011 | 8487 | 0.040 |
Why?
|
Analysis of Variance | 3 | 2021 | 6242 | 0.040 |
Why?
|
Genes, Tumor Suppressor | 1 | 2001 | 1056 | 0.030 |
Why?
|
Chromosomes, Human, Pair 17 | 1 | 2018 | 419 | 0.030 |
Why?
|
Clinical Competence | 2 | 2014 | 4786 | 0.030 |
Why?
|
Paraffin Embedding | 1 | 2018 | 302 | 0.030 |
Why?
|
Neoplasms, Radiation-Induced | 1 | 2001 | 549 | 0.030 |
Why?
|
Radiation Injuries | 1 | 1984 | 1183 | 0.030 |
Why?
|
Genetic Markers | 1 | 2003 | 2608 | 0.030 |
Why?
|
Lactation | 1 | 1999 | 395 | 0.030 |
Why?
|
Risk Management | 1 | 2020 | 558 | 0.030 |
Why?
|
Cell Differentiation | 4 | 2017 | 11480 | 0.030 |
Why?
|
Cell Polarity | 1 | 2020 | 638 | 0.030 |
Why?
|
Benzimidazoles | 1 | 2021 | 858 | 0.030 |
Why?
|
Formaldehyde | 1 | 2018 | 358 | 0.030 |
Why?
|
Brain Neoplasms | 1 | 2017 | 8984 | 0.030 |
Why?
|
Mediator Complex | 1 | 2016 | 106 | 0.030 |
Why?
|
beta Catenin | 1 | 2021 | 1043 | 0.030 |
Why?
|
Laboratories | 1 | 2000 | 461 | 0.030 |
Why?
|
Consensus Development Conferences as Topic | 1 | 2016 | 169 | 0.030 |
Why?
|
Gene Library | 3 | 2004 | 1060 | 0.030 |
Why?
|
Coronary Vessels | 5 | 1993 | 3112 | 0.030 |
Why?
|
Transforming Growth Factor alpha | 1 | 1996 | 135 | 0.030 |
Why?
|
Adiposity | 1 | 2005 | 1851 | 0.030 |
Why?
|
Vitamins | 1 | 2004 | 1635 | 0.030 |
Why?
|
Receptors, Cell Surface | 2 | 2007 | 2825 | 0.030 |
Why?
|
Fibrosis | 2 | 2012 | 2042 | 0.030 |
Why?
|
Mice, SCID | 2 | 2011 | 2627 | 0.030 |
Why?
|
Ubiquitin-Protein Ligases | 1 | 2024 | 1890 | 0.030 |
Why?
|
Population Surveillance | 2 | 2017 | 2609 | 0.030 |
Why?
|
Pregnancy | 4 | 2013 | 29725 | 0.030 |
Why?
|
Aromatase Inhibitors | 1 | 2019 | 511 | 0.030 |
Why?
|
Adolescent Behavior | 1 | 2003 | 1183 | 0.030 |
Why?
|
Vacuum | 1 | 2014 | 66 | 0.030 |
Why?
|
Cell Adhesion Molecules | 2 | 2011 | 1602 | 0.030 |
Why?
|
Image Enhancement | 1 | 2005 | 2877 | 0.030 |
Why?
|
Kaplan-Meier Estimate | 2 | 2019 | 6545 | 0.030 |
Why?
|
Exercise | 1 | 2011 | 5783 | 0.030 |
Why?
|
Phosphoric Monoester Hydrolases | 1 | 2016 | 414 | 0.030 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2007 | 5230 | 0.030 |
Why?
|
Crohn Disease | 1 | 1987 | 2275 | 0.030 |
Why?
|
False Negative Reactions | 1 | 1995 | 574 | 0.030 |
Why?
|
Tunica Intima | 2 | 1993 | 459 | 0.030 |
Why?
|
Cytodiagnosis | 1 | 1998 | 432 | 0.030 |
Why?
|
RNA, Neoplasm | 3 | 2002 | 749 | 0.030 |
Why?
|
Interleukin-1 | 1 | 1997 | 1250 | 0.030 |
Why?
|
Growth Substances | 1 | 1996 | 768 | 0.030 |
Why?
|
Mastectomy, Subcutaneous | 1 | 1993 | 56 | 0.030 |
Why?
|
Intermediate Filaments | 1 | 2014 | 172 | 0.030 |
Why?
|
Antibodies, Monoclonal | 4 | 2007 | 9196 | 0.030 |
Why?
|
Health Care Surveys | 1 | 2000 | 2434 | 0.030 |
Why?
|
Hot Temperature | 1 | 2000 | 1435 | 0.030 |
Why?
|
Microdissection | 1 | 2013 | 151 | 0.030 |
Why?
|
Lung Neoplasms | 1 | 2017 | 13249 | 0.030 |
Why?
|
ROC Curve | 2 | 2014 | 3568 | 0.030 |
Why?
|
Antigens, Neoplasm | 2 | 2011 | 1999 | 0.030 |
Why?
|
DNA Methylation | 4 | 2010 | 4374 | 0.030 |
Why?
|
Epidermal Growth Factor | 1 | 1996 | 695 | 0.030 |
Why?
|
Hodgkin Disease | 1 | 2001 | 1381 | 0.030 |
Why?
|
Mice | 7 | 2024 | 81216 | 0.030 |
Why?
|
Estrogens | 1 | 1999 | 1520 | 0.030 |
Why?
|
Salvage Therapy | 2 | 2005 | 1266 | 0.030 |
Why?
|
Evaluation Studies as Topic | 3 | 1989 | 1628 | 0.030 |
Why?
|
Angioplasty, Balloon | 2 | 1987 | 597 | 0.030 |
Why?
|
Tomography, Optical Coherence | 1 | 2005 | 2878 | 0.030 |
Why?
|
False Positive Reactions | 2 | 2005 | 956 | 0.030 |
Why?
|
Quality of Life | 2 | 2012 | 13300 | 0.030 |
Why?
|
Keratin-6 | 1 | 2011 | 18 | 0.020 |
Why?
|
Angioplasty, Laser | 1 | 1991 | 18 | 0.020 |
Why?
|
Mice, Inbred C3H | 1 | 1993 | 915 | 0.020 |
Why?
|
Methylation | 1 | 2014 | 1080 | 0.020 |
Why?
|
Treatment Failure | 3 | 2006 | 2646 | 0.020 |
Why?
|
Micronutrients | 1 | 2014 | 380 | 0.020 |
Why?
|
Entosis | 1 | 2011 | 6 | 0.020 |
Why?
|
Flow Cytometry | 2 | 2013 | 5873 | 0.020 |
Why?
|
Biological Evolution | 1 | 2017 | 1074 | 0.020 |
Why?
|
Receptors, Calcitriol | 1 | 2014 | 359 | 0.020 |
Why?
|
Dietary Supplements | 1 | 2004 | 3389 | 0.020 |
Why?
|
Cell Adhesion | 2 | 2008 | 3096 | 0.020 |
Why?
|
Tumor Suppressor Proteins | 1 | 2001 | 2804 | 0.020 |
Why?
|
Integrin alpha6 | 1 | 2010 | 30 | 0.020 |
Why?
|
Epidemiologic Studies | 1 | 2014 | 670 | 0.020 |
Why?
|
Multicenter Studies as Topic | 1 | 1996 | 1723 | 0.020 |
Why?
|
Mice, Nude | 2 | 2009 | 3605 | 0.020 |
Why?
|
Molecular Sequence Data | 4 | 2011 | 17628 | 0.020 |
Why?
|
Poly(ADP-ribose) Polymerases | 1 | 2012 | 428 | 0.020 |
Why?
|
Metaplasia | 1 | 2011 | 320 | 0.020 |
Why?
|
Nutritional Requirements | 1 | 2012 | 275 | 0.020 |
Why?
|
Body Height | 1 | 2016 | 1570 | 0.020 |
Why?
|
Fluorescent Antibody Technique, Direct | 1 | 2009 | 66 | 0.020 |
Why?
|
Lysine | 1 | 2014 | 1002 | 0.020 |
Why?
|
Adipose Tissue | 1 | 2002 | 3293 | 0.020 |
Why?
|
Transforming Growth Factor beta | 2 | 2008 | 1956 | 0.020 |
Why?
|
Cytokinesis | 1 | 2011 | 172 | 0.020 |
Why?
|
Temperature | 1 | 1996 | 2221 | 0.020 |
Why?
|
Endothelium, Vascular | 2 | 1999 | 4437 | 0.020 |
Why?
|
Thrombospondin 1 | 2 | 2002 | 257 | 0.020 |
Why?
|
Medical Audit | 1 | 2010 | 453 | 0.020 |
Why?
|
Japan | 1 | 1993 | 1369 | 0.020 |
Why?
|
Cathepsin K | 1 | 2008 | 65 | 0.020 |
Why?
|
Neprilysin | 1 | 2011 | 472 | 0.020 |
Why?
|
Intercellular Signaling Peptides and Proteins | 1 | 1996 | 1655 | 0.020 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2013 | 612 | 0.020 |
Why?
|
BRCA2 Protein | 1 | 2013 | 797 | 0.020 |
Why?
|
Paget Disease, Extramammary | 1 | 1988 | 51 | 0.020 |
Why?
|
Chromosomes, Human, Pair 16 | 1 | 2009 | 342 | 0.020 |
Why?
|
Cells, Cultured | 3 | 2013 | 18968 | 0.020 |
Why?
|
Glycoproteins | 1 | 1996 | 2208 | 0.020 |
Why?
|
User-Computer Interface | 1 | 2014 | 1402 | 0.020 |
Why?
|
Insulin-Like Growth Factor Binding Protein 3 | 1 | 2010 | 415 | 0.020 |
Why?
|
Arteriosclerosis | 1 | 1992 | 1064 | 0.020 |
Why?
|
Myosin Type II | 1 | 2007 | 70 | 0.020 |
Why?
|
Angioplasty, Balloon, Coronary | 2 | 1992 | 1880 | 0.020 |
Why?
|
Microarray Analysis | 1 | 2010 | 747 | 0.020 |
Why?
|
Fluorouracil | 2 | 1989 | 1630 | 0.020 |
Why?
|
Adherens Junctions | 1 | 2007 | 89 | 0.020 |
Why?
|
Chromosomes, Human, Pair 1 | 1 | 2009 | 635 | 0.020 |
Why?
|
Radionuclide Imaging | 2 | 2002 | 1975 | 0.020 |
Why?
|
Down-Regulation | 2 | 2005 | 2918 | 0.020 |
Why?
|
Cyclooxygenase 2 Inhibitors | 1 | 2009 | 321 | 0.020 |
Why?
|
Fibronectins | 2 | 2002 | 721 | 0.020 |
Why?
|
Chromosome Aberrations | 1 | 2013 | 1767 | 0.020 |
Why?
|
Keratin-14 | 1 | 2006 | 56 | 0.020 |
Why?
|
Cytokines | 1 | 2001 | 7345 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2012 | 10829 | 0.020 |
Why?
|
Immunochemistry | 1 | 1986 | 119 | 0.020 |
Why?
|
Hematoporphyrins | 1 | 1985 | 23 | 0.020 |
Why?
|
rho GTP-Binding Proteins | 1 | 2007 | 277 | 0.020 |
Why?
|
Mice, Inbred NOD | 1 | 2010 | 1837 | 0.020 |
Why?
|
Reoperation | 2 | 2006 | 4292 | 0.020 |
Why?
|
rho-Associated Kinases | 1 | 2007 | 281 | 0.020 |
Why?
|
California | 1 | 2010 | 1416 | 0.020 |
Why?
|
Esophagus | 1 | 1992 | 1023 | 0.020 |
Why?
|
Methotrexate | 2 | 1989 | 1717 | 0.020 |
Why?
|
Actuarial Analysis | 3 | 1994 | 375 | 0.020 |
Why?
|
Primary Prevention | 1 | 2013 | 1207 | 0.020 |
Why?
|
Matrix Metalloproteinase 13 | 1 | 2005 | 102 | 0.020 |
Why?
|
Vaginal Smears | 1 | 1988 | 495 | 0.020 |
Why?
|
Cluster Analysis | 1 | 2012 | 2698 | 0.020 |
Why?
|
Vinblastine | 1 | 2007 | 487 | 0.020 |
Why?
|
Actins | 2 | 2007 | 2049 | 0.020 |
Why?
|
Green Fluorescent Proteins | 1 | 2011 | 2056 | 0.020 |
Why?
|
Coronary Artery Bypass | 2 | 1992 | 2273 | 0.020 |
Why?
|
Collagenases | 1 | 2005 | 221 | 0.020 |
Why?
|
Heart Valves | 1 | 1987 | 285 | 0.020 |
Why?
|
Algorithms | 2 | 2021 | 13967 | 0.020 |
Why?
|
Loss of Heterozygosity | 1 | 2007 | 659 | 0.020 |
Why?
|
Poisson Distribution | 1 | 2006 | 507 | 0.020 |
Why?
|
Histocytochemistry | 1 | 1986 | 693 | 0.020 |
Why?
|
Chromosome Deletion | 1 | 2009 | 1387 | 0.020 |
Why?
|
Rabbits | 2 | 2008 | 4773 | 0.020 |
Why?
|
Meninges | 1 | 1986 | 197 | 0.020 |
Why?
|
Membrane Glycoproteins | 1 | 1996 | 3731 | 0.020 |
Why?
|
Rats | 1 | 2001 | 23695 | 0.010 |
Why?
|
Hematopoiesis | 1 | 2014 | 2063 | 0.010 |
Why?
|
Laparoscopy | 1 | 2016 | 2155 | 0.010 |
Why?
|
Amino Acid Sequence | 3 | 2002 | 13456 | 0.010 |
Why?
|
Mitotic Index | 1 | 1984 | 161 | 0.010 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2012 | 936 | 0.010 |
Why?
|
Aortic Valve Stenosis | 2 | 1987 | 2064 | 0.010 |
Why?
|
Equipment Design | 1 | 1992 | 3520 | 0.010 |
Why?
|
Palpation | 1 | 2004 | 166 | 0.010 |
Why?
|
Prevalence | 2 | 2008 | 15687 | 0.010 |
Why?
|
Genetic Heterogeneity | 1 | 2007 | 724 | 0.010 |
Why?
|
Probability | 1 | 1989 | 2476 | 0.010 |
Why?
|
Carcinoma, Medullary | 1 | 2004 | 115 | 0.010 |
Why?
|
Microscopy, Fluorescence | 1 | 2011 | 2651 | 0.010 |
Why?
|
Haplotypes | 1 | 2010 | 2764 | 0.010 |
Why?
|
Teratoma | 1 | 1986 | 403 | 0.010 |
Why?
|
Massachusetts | 2 | 2010 | 8805 | 0.010 |
Why?
|
Genital Neoplasms, Female | 1 | 1988 | 538 | 0.010 |
Why?
|
Models, Biological | 2 | 2011 | 9468 | 0.010 |
Why?
|
Fibroblasts | 1 | 2013 | 4091 | 0.010 |
Why?
|
Life Style | 1 | 2014 | 3888 | 0.010 |
Why?
|
Signal Transduction | 3 | 2013 | 23363 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 1999 | 14482 | 0.010 |
Why?
|
Microscopy, Electron | 1 | 1986 | 2558 | 0.010 |
Why?
|
Ectodysplasins | 1 | 2002 | 11 | 0.010 |
Why?
|
Chemokine CXCL12 | 1 | 2004 | 454 | 0.010 |
Why?
|
Proto-Oncogene Proteins c-kit | 1 | 2006 | 729 | 0.010 |
Why?
|
Lysosomes | 1 | 2007 | 919 | 0.010 |
Why?
|
Health Surveys | 1 | 2012 | 4061 | 0.010 |
Why?
|
Kidney | 1 | 2017 | 7072 | 0.010 |
Why?
|
Mucin-1 | 1 | 1986 | 539 | 0.010 |
Why?
|
Chi-Square Distribution | 2 | 2002 | 3466 | 0.010 |
Why?
|
Vascular Surgical Procedures | 1 | 1990 | 1469 | 0.010 |
Why?
|
Endocarditis, Bacterial | 1 | 1985 | 445 | 0.010 |
Why?
|
Premenopause | 1 | 2005 | 1039 | 0.010 |
Why?
|
Hypogonadism | 1 | 1987 | 800 | 0.010 |
Why?
|
Clinical Trials as Topic | 3 | 2013 | 8058 | 0.010 |
Why?
|
Cross-Sectional Studies | 2 | 2014 | 25928 | 0.010 |
Why?
|
Cell Line | 2 | 2011 | 15626 | 0.010 |
Why?
|
Neurilemmoma | 1 | 1986 | 523 | 0.010 |
Why?
|
Streptococcal Infections | 1 | 1985 | 617 | 0.010 |
Why?
|
Metabolic Diseases | 1 | 1987 | 685 | 0.010 |
Why?
|
Subcellular Fractions | 1 | 2002 | 532 | 0.010 |
Why?
|
Models, Genetic | 1 | 2011 | 3442 | 0.010 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2009 | 3584 | 0.010 |
Why?
|
Muscle, Smooth | 1 | 2004 | 924 | 0.010 |
Why?
|
NF-kappa B | 1 | 2009 | 2486 | 0.010 |
Why?
|
Diet Surveys | 1 | 2004 | 1161 | 0.010 |
Why?
|
Growth Inhibitors | 1 | 2001 | 378 | 0.010 |
Why?
|
Stents | 1 | 1992 | 3303 | 0.010 |
Why?
|
Radiography | 2 | 1991 | 6965 | 0.010 |
Why?
|
Coronary Angiography | 4 | 1993 | 4560 | 0.010 |
Why?
|
Extracellular Matrix | 1 | 2007 | 1726 | 0.010 |
Why?
|
Testicular Neoplasms | 1 | 1986 | 800 | 0.010 |
Why?
|
Blotting, Northern | 1 | 2001 | 1544 | 0.010 |
Why?
|
Versicans | 1 | 1999 | 40 | 0.010 |
Why?
|
Decorin | 1 | 1999 | 38 | 0.010 |
Why?
|
Pedigree | 1 | 2007 | 4577 | 0.010 |
Why?
|
Cricetulus | 1 | 2001 | 815 | 0.010 |
Why?
|
Genotype | 1 | 2014 | 12959 | 0.010 |
Why?
|
COS Cells | 1 | 2001 | 1129 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2010 | 15766 | 0.010 |
Why?
|
Collagen | 2 | 1999 | 2635 | 0.010 |
Why?
|
Neoplastic Stem Cells | 1 | 2007 | 1347 | 0.010 |
Why?
|
Chondroitin Sulfate Proteoglycans | 1 | 1999 | 141 | 0.010 |
Why?
|
CHO Cells | 1 | 2001 | 1389 | 0.010 |
Why?
|
Cost Savings | 1 | 2004 | 920 | 0.010 |
Why?
|
Collagen Type I | 1 | 2002 | 615 | 0.010 |
Why?
|
Vegetables | 1 | 2003 | 1198 | 0.010 |
Why?
|
Preoperative Care | 1 | 2007 | 2255 | 0.010 |
Why?
|
Cricetinae | 1 | 2001 | 2427 | 0.010 |
Why?
|
Bayes Theorem | 1 | 2006 | 2325 | 0.010 |
Why?
|
Stomach Neoplasms | 1 | 2007 | 1423 | 0.010 |
Why?
|
Homeostasis | 1 | 2008 | 3305 | 0.010 |
Why?
|
Sequence Homology, Amino Acid | 1 | 2001 | 2755 | 0.010 |
Why?
|
Sequence Alignment | 1 | 2001 | 2178 | 0.010 |
Why?
|
Child | 3 | 2016 | 79758 | 0.010 |
Why?
|
Cholesterol | 1 | 1986 | 2925 | 0.010 |
Why?
|
Deoxyuracil Nucleotides | 1 | 1996 | 13 | 0.010 |
Why?
|
Coronary Artery Disease | 2 | 1993 | 6661 | 0.010 |
Why?
|
Gene Amplification | 1 | 2001 | 1085 | 0.010 |
Why?
|
Staphylococcal Infections | 1 | 1985 | 1405 | 0.010 |
Why?
|
RNA, Small Interfering | 1 | 2005 | 3443 | 0.010 |
Why?
|
DNA Nucleotidylexotransferase | 1 | 1996 | 66 | 0.010 |
Why?
|
Adenofibroma | 1 | 1996 | 25 | 0.010 |
Why?
|
Histocytological Preparation Techniques | 1 | 1996 | 33 | 0.010 |
Why?
|
Antioxidants | 1 | 2004 | 1668 | 0.010 |
Why?
|
Clostridium Infections | 1 | 1983 | 557 | 0.010 |
Why?
|
Aortic Valve | 1 | 1986 | 1996 | 0.010 |
Why?
|
Sodium Chloride | 1 | 1998 | 596 | 0.010 |
Why?
|
Proteoglycans | 1 | 1999 | 802 | 0.010 |
Why?
|
Drug Administration Schedule | 1 | 2004 | 4900 | 0.010 |
Why?
|
Lectins, C-Type | 1 | 1999 | 591 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2014 | 11902 | 0.010 |
Why?
|
Drug Costs | 1 | 2004 | 1184 | 0.010 |
Why?
|
Vascular Endothelial Growth Factor Receptor-1 | 1 | 1999 | 558 | 0.010 |
Why?
|
Catheterization | 2 | 1991 | 1432 | 0.010 |
Why?
|
Angiography | 2 | 1991 | 1605 | 0.010 |
Why?
|
Gene Silencing | 1 | 2001 | 1511 | 0.010 |
Why?
|
Extracellular Matrix Proteins | 1 | 1999 | 829 | 0.010 |
Why?
|
Breast Implants | 1 | 1998 | 411 | 0.010 |
Why?
|
Protein Isoforms | 1 | 1999 | 1697 | 0.010 |
Why?
|
GPI-Linked Proteins | 1 | 1996 | 468 | 0.010 |
Why?
|
Up-Regulation | 1 | 2003 | 4127 | 0.010 |
Why?
|
Decision Support Techniques | 1 | 2004 | 2002 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 2 | 1987 | 20484 | 0.010 |
Why?
|
Safety | 1 | 1998 | 1149 | 0.010 |
Why?
|
Psoriasis | 1 | 2002 | 939 | 0.010 |
Why?
|
von Willebrand Factor | 1 | 1997 | 673 | 0.010 |
Why?
|
Transfection | 1 | 2001 | 5782 | 0.010 |
Why?
|
Proto-Oncogene Proteins c-met | 1 | 1997 | 567 | 0.010 |
Why?
|
Skin Transplantation | 1 | 1998 | 1083 | 0.010 |
Why?
|
Recombinant Fusion Proteins | 1 | 2001 | 3735 | 0.010 |
Why?
|
Contrast Media | 1 | 2006 | 5301 | 0.010 |
Why?
|
Imaging, Three-Dimensional | 1 | 2006 | 4044 | 0.010 |
Why?
|
Cell Movement | 1 | 2004 | 5206 | 0.010 |
Why?
|
Intestinal Mucosa | 1 | 1983 | 3023 | 0.010 |
Why?
|
RNA | 1 | 2002 | 2721 | 0.010 |
Why?
|
Spinal Neoplasms | 1 | 1998 | 716 | 0.010 |
Why?
|
Confidence Intervals | 1 | 1997 | 2932 | 0.010 |
Why?
|
Family | 1 | 2002 | 3189 | 0.010 |
Why?
|
Esophageal Diseases | 1 | 1992 | 168 | 0.010 |
Why?
|
Genetic Testing | 1 | 2004 | 3530 | 0.010 |
Why?
|
Cell Death | 1 | 1996 | 1670 | 0.010 |
Why?
|
Radioisotope Teletherapy | 1 | 1989 | 15 | 0.010 |
Why?
|
Coronary Thrombosis | 1 | 1993 | 486 | 0.010 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 1997 | 3804 | 0.010 |
Why?
|
Promoter Regions, Genetic | 1 | 2001 | 5784 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2009 | 18134 | 0.010 |
Why?
|
Surgical Flaps | 1 | 1998 | 1666 | 0.010 |
Why?
|
Mucous Membrane | 1 | 1992 | 657 | 0.000 |
Why?
|
Constriction, Pathologic | 1 | 1991 | 1098 | 0.000 |
Why?
|
Genitalia, Female | 1 | 1988 | 147 | 0.000 |
Why?
|
Perineum | 1 | 1988 | 209 | 0.000 |
Why?
|
Urethra | 1 | 1988 | 406 | 0.000 |
Why?
|
Hematoporphyrin Derivative | 1 | 1985 | 10 | 0.000 |
Why?
|
DNA Damage | 1 | 1996 | 2442 | 0.000 |
Why?
|
Comorbidity | 1 | 2001 | 10552 | 0.000 |
Why?
|
Methods | 1 | 1986 | 1075 | 0.000 |
Why?
|
Intraoperative Period | 1 | 1987 | 516 | 0.000 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 1997 | 4357 | 0.000 |
Why?
|
Smoking | 1 | 2002 | 9070 | 0.000 |
Why?
|
Postoperative Period | 1 | 1990 | 1821 | 0.000 |
Why?
|
Emergencies | 1 | 1991 | 1217 | 0.000 |
Why?
|
Radiotherapy, High-Energy | 1 | 1985 | 228 | 0.000 |
Why?
|
Cervix Uteri | 1 | 1987 | 585 | 0.000 |
Why?
|
Uterus | 1 | 1987 | 651 | 0.000 |
Why?
|
Blindness | 1 | 1987 | 582 | 0.000 |
Why?
|
Deafness | 1 | 1987 | 456 | 0.000 |
Why?
|
Muscle, Skeletal | 1 | 1998 | 4923 | 0.000 |
Why?
|
Europe | 1 | 1989 | 3433 | 0.000 |
Why?
|
Feasibility Studies | 1 | 1993 | 5201 | 0.000 |
Why?
|
Intraoperative Care | 1 | 1986 | 768 | 0.000 |
Why?
|
Endoscopy | 1 | 1992 | 1841 | 0.000 |
Why?
|
Esophageal Neoplasms | 1 | 1992 | 1651 | 0.000 |
Why?
|
Syndrome | 1 | 1987 | 3278 | 0.000 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 1983 | 881 | 0.000 |
Why?
|
Brachytherapy | 1 | 1988 | 1240 | 0.000 |
Why?
|
Boston | 1 | 1992 | 9282 | 0.000 |
Why?
|
Colon | 1 | 1987 | 1788 | 0.000 |
Why?
|
Postoperative Complications | 2 | 1992 | 15680 | 0.000 |
Why?
|
Physical Examination | 1 | 1985 | 1244 | 0.000 |
Why?
|
Electrocardiography | 1 | 1990 | 6413 | 0.000 |
Why?
|
Patient Care Team | 1 | 1987 | 2510 | 0.000 |
Why?
|
Palliative Care | 1 | 1986 | 3607 | 0.000 |
Why?
|
Myocardial Infarction | 1 | 1990 | 11891 | 0.000 |
Why?
|